The update permits PARSOL Shield’s use in multifunctional topical product formulations where sun protection is not the primary function, including daily-wear skincare and color cosmetics.
‘A new generation of elegant and wearable formulas’
Until now, PARSOL Shield’s use in Canada was limited to products regulated under the Primary Sunscreen Monograph.
Speaking to CosmeticsDesign, Amy Ethier, PhD, regulatory affairs manager North America at dsm-firmenich explained that the expansion “unlocks the utility of PARSOL Shield as a highly photostable, broad spectrum UV filter.”
The February 27, 2026, update also revised the monograph language, removing a footnote tied to Table 2 that previously constrained certain formulation parameters, marking the revision as “even more significant” as it “expands formula design flexibility,” she added.
“This regulatory opens the door to a new generation of elegant and wearable formulas, giving formulators the freedom to design innovative everyday sun protective products,” she explained.
The change could translate into a wider range of formats reaching the Canadian market, including “high-performance options that fit seamlessly into modern beauty routines - an exciting step forward for skin health in Canada,” she said.
Safety and performance data supported the decision
According to Ethier, the ingredient’s existing approval for primary sunscreens helped support the expanded regulatory pathway.
“PARSOL Shield has a well-established global record of safe and effective use as a UV filter, and its existing approval under Canada’s Primary Sunscreen Monograph provides strong rationale for extending its use into products where sun protection is a secondary function,” Ethier said.
She noted that the ingredient has been evaluated across multiple study types.
“The safety of PARSOL Shield has been consistently reinforced through nonclinical, clinical, absorption, and long-term studies, and its proven broad-spectrum performance, even at low levels, supports high quality formulation across categories,” Ethier explained.
“Together, these factors support Health Canada’s decision to grant broader approval, helping ensure Canadian consumers gain access to products that compete on a more globally aligned playing field,” she added.
Canadian decision arrives as U.S. review continues
The update also comes as U.S. regulators continue evaluating Bemotrizinol for potential inclusion in the over-the-counter sunscreen monograph.
“Health Canada’s addition of Bemotrizinol (PARSOL Shield) to the Secondary Sunscreen Monograph strengthens dsm-firmenich’s global regulatory momentum by validating the ingredient’s robust safety, efficacy, and photostability profile under another major regulatory authority,” Carl D’Ruiz, MPH, senior manager of science, advocacy and business development at dsm-firmenich, told CosmeticsDesign.
The ingredient is currently under review by the U.S. Food and Drug Administration, and according to D’Ruiz, international regulatory approvals may help strengthen the case toward broader adoption.
“The growing convergence among Canadian, European, Asian, and Australian regulators reinforces international confidence in a filter that has been widely used globally for more than two decades,” D’Ruiz said.
“By confirming the same safety and performance data currently under FDA review - spanning clinical, nonclinical, dermal absorption, and long-term safety studies - Health Canada’s decision helps strengthen the scientific foundation supporting U.S. approval,” he added.
What does this mean for global product development?
For product developers, broader regulatory coordination can reduce complexity in cross-regional formulation strategies.
“PARSOL Shield simplifies cross regional development by bringing broad regulatory alignment and high formulation flexibility,” D’Ruiz said.
“With approval across major markets and now inclusion in Canada’s Secondary Sunscreen Monograph up to 6%, brands can build a single global chassis and adapt it with minimal regional tweaks—reducing duplicate testing and development cycles,” he explained.
If the ingredient ultimately receives approval in the United States, companies could accelerate product launches.
“As the U.S. FDA moves toward allowing up to 6% via its Tier 1 OMOR process (final order expected by June 2026, effective 60 calendar days later), formulators gain even greater harmonization, enabling portfolios that are U.S.-ready at or near launch,” D’Ruiz said.
The ingredient’s technical characteristics may also simplify filter systems.
“Beyond regulatory alignment, PARSOL Shield’s photostability, broad spectrum efficiency at low concentrations, and high compatibility with both organic and inorganic filters allow teams to hit global SPF/UVA targets with leaner, more consistent filter systems,” D’Ruiz noted.
Opportunities in daily skincare and hybrid formats
Manufacturers working in multifunctional categories may see the most immediate impact.
“Brands can deliver higher SPF/UVA protection with lighter, more elegant textures, thanks to PARSOL Shield’s efficiency and photostability,” D’Ruiz said.
“This reduces whitening and supports simple, ‘apply-and-go’ formulas,” he added.
In color cosmetics, the ingredient may help maintain shade consistency.
“Expect better shade integrity and less white-cast, even in deeper tones, because PARSOL Shield enables sheer, non-whitening finishes,” D’Ruiz said.
The ingredient’s compatibility with oils and active ingredients may also support multifunctional product design.
“PARSOL Shield’s compatibility with oils and actives makes it easier to combine SPF with antioxidants, barrier lipids, and treatment ingredients in a single formula—reducing the need for separate ‘SPF’ and ‘treatment’ SKUs,” D’Ruiz explained.
“With Canada allowing up to 6% in multi-functional products and the U.S. moving toward approval, brands can prepare rapid claim and label upgrades,” he added.
